



Imayk 462418

FEE TRANSMITTAL for FY 2004		Complete if Known	
Effective 10/01/2003, Patent fees are subject to annual revision.		Application Number	09/724277
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	November 28, 2000
		First Named Inventor	Oivin Guicherit
		Examiner Name	D. R. Rao
		Art Unit	1624
TOTAL AMOUNT OF PAYMENT (\$)		Attorney Docket No.	CIBT-P04-072
180.00			
METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		3. ADDITIONAL FEES	
<input checked="" type="checkbox"/> Deposit Account:		Large Entity Small Entity	
Deposit Account Number 18-1945		Fee Code Fee (\$) Fee Code Fee (\$)	
Deposit Account Name Ropes & Gray LLP		Fee Description Fee Paid	
The Director is authorized to: (check all that apply)		1051 130 2051 65 Surcharge - late filing fee or oath	
<input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments		1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet.	
<input checked="" type="checkbox"/> Charge any additional fee(s) or any underpayment of fee(s)		1053 130 1053 130 Non-English specification	
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.		1812 2,520 1812 2,520 For filing a request for ex parte reexamination	
FEE CALCULATION		1804 920* 1804 920* Requesting publication of SIR prior to Examiner action	
1. BASIC FILING FEE		1805 1,840* 1805 1,840* Requesting publication of SIR after Examiner action	
Large Entity Small Entity		1251 110 2251 55 Extension for reply within first month	
Fee Code Fee (\$) Fee Code Fee (\$)		1252 420 2252 210 Extension for reply within second month	
1001 770 2001 385 Utility filing fee		1253 950 2253 475 Extension for reply within third month	
1002 340 2002 170 Design filing fee		1254 1,480 2254 740 Extension for reply within fourth month	
1003 530 2003 265 Plant filing fee		1255 2,010 2255 1,005 Extension for reply within fifth month	
1004 770 2004 385 Reissue filing fee		1401 330 2401 165 Notice of Appeal	
1005 160 2005 80 Provisional filing fee		1402 330 2402 165 Filing a brief in support of an appeal	
SUBTOTAL (1) (\$)		1403 290 2403 145 Request for oral hearing	
0.00		1451 1,510 1451 1,510 Petition to institute a public use proceeding	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE		1452 110 2452 55 Petition to revive - unavoidable	
Total Claims ** = Extra Claims Fee from below Fee Paid		1453 1,330 2453 665 Petition to revive - unintentional	
Independent Claims ** =		1501 1,330 2501 665 Utility issue fee (or reissue)	
Multiple Dependent		1502 480 2502 240 Design issue fee	
Large Entity Small Entity		1503 640 2503 320 Plant issue fee	
Fee Code Fee (\$) Fee Code Fee (\$)		1460 130 1460 130 Petitions to the Commissioner	
1202 18 2202 9 Claims in excess of 20		1807 50 1807 50 Processing fee under 37 CFR 1.17(q)	
1201 86 2201 43 Independent claims in excess of 3		1806 180 1806 180 Submission of Information Disclosure Stmt	
1203 290 2203 145 Multiple dependent claim, if not paid		8021 40 8021 40 Recording each patent assignment per property (times number of properties)	
1204 86 2204 43 ** Reissue independent claims over original patent		1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent		1810 770 2810 385 For each additional invention to be examined (37CFR 1.129(b))	
SUBTOTAL (2) (\$)		1801 770 2801 385 Request for Continued Examination (RCE)	
0.00		1802 900 1802 900 Request for expedited examination of a design application	
** or number previously paid, if greater; For Reissues, see above		Other fee (specify)	
		SUBTOTAL (3) (\$)	
		180.00	
SUBMITTED BY		(Complete if applicable)	
Name (Print/Type) David P. Halstead		Registration No. 44,735	
Signature [Signature]		Telephone (617) 951-7615	
		Date March 19, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: 3/19/04 Signature: Valerie J. Sarosky (Valerie J. Sarosky)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3/19/04

Signature:

(Valerie J. Sarosky)

Docket No.: CIBT-P04-072
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Guicherit et al.

Application No.: 09/724277

Confirmation No.: 7556

Filed: November 28, 2000

Art Unit: 1624

For: MEDIATORS OF HEDGEHOG SIGNALING
PATHWAYS, COMPOSITIONS AND USES
RELATED THERETO

Examiner: D. R. Rao

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Copies of the references on the PTO/SB/08 are not provided because they were previously cited by or submitted to the Office in a prior application number 09/663835, filed September 15, 2000 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

03/23/2004 JADD01 00000094 181945 09724277

01 FC:1806 180.00 DA

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CIBT-P04-072.

Dated: March 19, 2004

Respectfully submitted,

By 

David P. Halstead

Registration No.: 44,735
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/724277		
		Filing Date	November 28, 2000		
		First Named Inventor	Oivin Guicherit		
		Art Unit	1624		
		Examiner Name	D. R. Rao		
Sheet	1	of	2	Attorney Docket Number	CIBT-P04-072

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,869,665	02/1999	Padia	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 99/10004	03/1999	Bladgen et al.		
	BB	EP 0 056 637 A	07-28-1982			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	BALE et al., "The hedgehog pathway and basal cell carcinomas," Human Molecular Genetics, Vol. 10, No. 7, pp. 757-762 (2001).		
	CB	BADAWY, M. et al., "Chemistry of Quinazolines: Reinvestigation of the Action of Hydrazine on Thioxo Derivatives," J. Heterocyclic Chem. 22: 1535-1536 (1985).		
	CC	BARTOLI, J. et al., "New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(23H)-quinazolinones," J. Med. Chem. 41: 1869-1882 (1998).		
	CD	BRANA, M. et al., "Synthesis of New Derivatives of β -Carboline-hydantoin," J. Heterocyclic Chem. 27: 703-706 (1990).		
	CE	KULKARNI, Y. et al., "Possible Antifertility Agents. Part-I. Synthesis of 2-(N,N-Substituted-aminomethyl 1)-3-(2-pyridyl)-4(3H)-oxo-3,l-quinazolines," J. Indian Chem. Soc. LXI: 720-721 (August 1984).		
	CF	LOPEZ-RODRIGUEZ, M. et al., "Stereospecificity in the Reaction of Tetrahydro- β -carboline-3-carboxylic Acids with Isocyanates and Isothiocyanates. Kinetic vs Thermodynamic Control," J. Org. Chem. 59: 1583-1585 (1994).		
	CG	MAJO, V. and PERUMAL, P., "Dimerization of Substituted 2-Aminobenzoic Acids Under Vilsmeier Conditions: A Novel Route to the Synthesis of 4-(3H)-Quinazolinones," Tetrahedron Letters 37 (28): 5015-5018 (1996).		
	CH	MAYER, J. et al., "Solid Phase Synthesis of Quinazolinones," Tetrahedron Letters 38 (49): 8445-8448 (1997).		
	CI	PADIA, J. et al., "Design and Synthesis of Novel Nonpeptide CCK-B Receptor Antagonists," Bioorganic & Medicinal Chem. Letters 7 (7): 805-810 (1997).		
	CJ	PADIA, J. et al., "Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists," J. Med. Chem. 41: 1042-1049 (1998).		
	CK	PRASHAD, M. et al., "Reaction of Benzoyleneurea and Isatoic Anhydride with the Vilsmeier Reagent," Tetrahedron Letters 38 (8): 1313-1316 (1997).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/724277
				Filing Date	November 28, 2000
				First Named Inventor	Oivin Guicherit
				Art Unit	1624
				Examiner Name	D. R. Rao
Sheet	2	of	2	Attorney Docket Number	CIBT-P04-072

CL	RATHMAN, T. et al., "Functionalization of 2-Methyl-3-o-totyl-4(3H)-quinazolinone and Related Compounds through Carbanion Reactions at the 2-Methyl Group," J. Org. Chem. 45: 2069-2176 (1980).
CM	VILLAGORDO, J. et al., "Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig-Mediated Annulation Strategy," Synlett 12: 1405-1407 (December 1998).
CN	WANG, H. and GANESAN, A., "Total Synthesis of the Quinazoline Alkaloids (-)-Fumiquinazoline G and (-)-Fiscalin B," J. Org. Chem. 63: 2432-2433 (1998).
CO	WUCKELT, J. et al., "Efficient Synthesis of Quinazolin-4-ones and Axially Chiral 2,2' -Bis-quinazolin-4-ones by Reaction of Anthranilic Acid Derived Nucleophiles with Oxalic Acid-Bis(imidoyl)chlorides," Synlett 7: 1100-1102 (1999).
CP	YU, M. et al., "Synthesis and X-Ray Crhstallographic Analysis of Quinazolinone Cholecystokinin/Gastrin Receptor Ligands," J. Med. Chem 35: 2534-2542 (1992).
CQ	ZAHER, H. et al., "Reactions of 2-p-Anizyl-3(4H), 1-benzoxazin-4-one with Ammonia, Primary Amines, Hydrazine, Phenylhydrazine & Grignardn Reagents," Indian J. Chem. 12: 1212-1215 (1974).
CR	ZENTMYER, D. and WAGNER, E., "The So-called Acylantranils (3,1,4-Benzoxazones). I. Preparation; Reactions with Water, Ammonia, and Aniline; Structure," J. Org. Chem. XIV: 967-981 (1949).
CS	A. RAO et al., "Synthesis and Biological Activities of Certain Derivatives of 3-Aryl-4(3H)-Quinazolinones.II," Journal of Indian Chem. Soc. 62 (3): 234-236 (March 1985).
CT	BUDDHA DEO SINGH, "4-Quinazolones.II," Journal of Indian Chem. Soc. 46 (1): 23-24 (January 1969).
CU	Chemical Abstracts, Vol. 96, No. 28, Abstract No. 142790P, Columbus, Ohio (1982).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--